Daiichi Sankyo Co Ltd 2024 IR
The report highlights Daiichi Sankyo's progress in FY2023, particularly the expansion of its oncology business and the strategic alliance with Merck & Co. for three DXd ADC products. The company successfully supplied DAICHIRONA, Japan's first mRNA vaccine for COVID-19, and joined the RE100 initiative to transition to 100% renewable energy. Financially, revenue reached 1,601.7 billion yen, with a target of 2.1 trillion yen for FY2025. The company also advanced its human capital strategy by establishing the Daiichi Sankyo Group People Philosophy and launching the DS Academy to develop global leaders.
Company: Daiichi Sankyo Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2024
Type: IR
Pages: 56
Back to company
Daiichi Sankyo Co Ltd
Value Report
The report highlights Daiichi Sankyo's progress in FY2023, particularly the expansion of its oncology business and the strategic alliance with Merck & Co. for three DXd ADC products. The company successfully supplied DAICHIRONA, Japan's first mRNA vaccine for COVID-19, and joined the RE100 initiative to transition to 100% renewable energy. Financially, revenue reached 1,601.7 billion yen, with a target of 2.1 trillion yen for FY2025. The company also advanced its human capital strategy by establishing the Daiichi Sankyo Group People Philosophy and launching the DS Academy to develop global leaders.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees